Zuckerman Investment Group LLC Invests $147,000 in Tilray Brands, Inc. $TLRY

Zuckerman Investment Group LLC bought a new position in shares of Tilray Brands, Inc. (NASDAQ:TLRY) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 85,000 shares of the company’s stock, valued at approximately $147,000.

Several other hedge funds have also recently added to or reduced their stakes in TLRY. Silverlake Wealth Management LLC purchased a new position in Tilray Brands in the third quarter worth approximately $25,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Tilray Brands in the 3rd quarter valued at approximately $25,000. Unified Investment Management acquired a new stake in shares of Tilray Brands in the 3rd quarter valued at $26,000. J.W. Cole Advisors Inc. raised its holdings in shares of Tilray Brands by 203.2% in the 2nd quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock valued at $30,000 after purchasing an additional 48,177 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Tilray Brands during the 3rd quarter worth $30,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on TLRY shares. Canaccord Genuity Group began coverage on shares of Tilray Brands in a research note on Tuesday, January 27th. They set a “hold” rating for the company. Roth Mkm cut their price target on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. Wall Street Zen downgraded Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Zacks Research raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Finally, ATB Cormark Capital Markets upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 10th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Tilray Brands has a consensus rating of “Hold” and a consensus price target of $13.33.

Tilray Brands Price Performance

Shares of TLRY opened at $6.89 on Friday. Tilray Brands, Inc. has a 1-year low of $3.51 and a 1-year high of $23.20. The stock has a market cap of $802.75 million, a PE ratio of -0.31 and a beta of 1.96. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The firm has a fifty day moving average price of $8.08 and a 200 day moving average price of $10.79.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings data on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.12. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.The company had revenue of $217.51 million for the quarter, compared to analyst estimates of $211.15 million. During the same quarter last year, the company posted ($0.03) earnings per share. As a group, sell-side analysts anticipate that Tilray Brands, Inc. will post -0.2 EPS for the current year.

Tilray Brands Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.